Bromfenac Ophthalmic Solution, 0.07%

BROMFENAC SODIUM OPHTHALMIC HUMAN PRESCRIPTION DRUG

Bromfenac Ophthalmic Solution, 0.07% is an FDA drug label for the active ingredient BROMFENAC SODIUM manufactured by Apotex Corp. administered by OPHTHALMIC. This page reproduces the FDA-approved indications and usage, dosage, contraindications, warnings, and adverse reactions exactly as published in the drug label. Data source: openFDA (U.S. FDA), label effective 20260615.

Generic name
BROMFENAC SODIUM
Manufacturer
Apotex Corp.
Product type
HUMAN PRESCRIPTION DRUG
Route
OPHTHALMIC
Dosage form
N/A
NDC
60505-1006
Application
ANDA207334
Label effective
20260615

About this product

Bromfenac Ophthalmic Solution, 0.07% is an FDA-registered drug product whose active ingredient is BROMFENAC SODIUM. It is labelled by Apotex Corp. taken by ophthalmic and marketed as a human prescription drug product. Identifiers on file: NDC 60505-1006, application ANDA207334, label effective 20260615. It is one of 4 FDA drug label records sharing the active ingredient BROMFENAC SODIUM. This page reproduces the FDA-approved label text so you can check what a product is, who makes it and how it is supplied before discussing it with a pharmacist or prescriber.

What it is used for

Across FDA labelling, products containing BROMFENAC SODIUM are most often described in connection with: bromfenac ophthalmic, treatment postoperative, reduction ocular, pain patients, undergone cataract, solution indicated, nonsteroidal anti-inflammatory, drug nsaid. Wording differs between labels, and the full indications section on this page takes precedence when it is present.

Indications & Usage

1 INDICATIONS AND USAGE Bromfenac Ophthalmic Solution, 0.07% is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. Bromfenac Ophthalmic Solution, 0.07% is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. ( 1 )

Dosage & Administration

2 DOSAGE AND ADMINISTRATION Instill one drop into the affected eye once daily beginning 1 day prior to surgery, continued on the day of surgery, and through the first 14 days postsurgery. ( 2.1 ) 2.1 Recommended Dosage Apply one drop to the affected eye once daily beginning 1 day prior to cataract surgery, continued on the day of surgery, and through the first 14 days of the postoperative period. 2.2 Use with Other Topical Ophthalmic Medications Bromfenac ophthalmic solution, 0.07% may be administered in conjunction with other topical ophthalmic medications such as alpha agonists, beta-blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics. Drops should be administered at least 5 minutes apart.

Contraindications

4 CONTRAINDICATIONS None. None. ( 4 )

Adverse Reactions

6 ADVERSE REACTIONS The most commonly reported adverse reactions in 3% to 8% of patients were anterior chamber inflammation, foreign body sensation, eye pain, photophobia, and blurred vision. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Apotex Corp. at 1-800-706-5575 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The most commonly reported adverse reactions following use of bromfenac ophthalmic solution, 0.07% following cataract surgery include: anterior chamber inflammation, foreign body sensation, eye pain, photophobia, and vision blurred. These reactions were reported in 3% to 8% of patients.

More products with the same ingredient

BROMFENAC SODIUM

Prolensa

Bausch & Lomb Incorporated View label

bromfenac ophthalmic solution

Dr. Reddy's Laboratories Inc. View label

bromfenac ophthalmic solution

Bausch & Lomb Americas Inc. View label

How products containing BROMFENAC SODIUM compare

FDA lists 4 drug label records with BROMFENAC SODIUM as the active ingredient. The most common dosage forms and the manufacturers with the most records are summarised below; strengths, pack sizes and inactive ingredients can still differ between apparently similar products.

Dosage formProductsManufacturerProducts
— — Apotex Corp. 1
— — Bausch & Lomb Americas Inc. 1
— — Bausch & Lomb Incorporated 1
— — Dr. Reddy's Laboratories Inc. 1
— — — —

Recall and safety notices

5 FDA recall record(s) match this product name or manufacturer. A match means the firm or product name appears in the enforcement report; confirm lot numbers and dates against the official FDA notice before acting.

RecallProductFirmClassStatusReported
D-0877-2026 Paroxetine Extended-Release Tablets, 37.5mg, 30-count bottle, Rx only, Manufactured by: Apotex Inc., Toronto, Ontario, Canada M9L 1T9, Manufactured for: Apotex Corp., Weston, Florida 33326, NDC 60505-1318-3 Apotex Corp. Class II Ongoing 20261007
D-0804-2026 Paxil CR, Paroxetine, Extended-Release Tablets, 37.5mg, 30 count bottle, Rx only, Manufactured by: Apotex Inc., Toronto, Ontario, Canada M9L 1T9, Manufactured for: Apotex Corp., Weston, Florida 33326, NDC 60505-4379-3 Apotex Corp. Class II Ongoing 20260902
D-0510-2026 Desmopressin Nasal Spray, USP, 10 mcg/0.1 mL, 5 mL bottle (50 doses), Rx only, Mfg by: Apotek inc., Toronto, Ontario, Canada, M9L 1T9, Mfg for: Apotek Corp., Weston, FL 33326, NDC 60505-0815-0 Apotex Corp. Class II Ongoing 20260422
D-0407-2026 Brimonidine Tartrate/Timolol Maleate Ophthalmic Solution 0.2%/0.5%*, 5 mL, Rx Only, Sterile, Apotex Corp. Manufactured for: Apotex Corp., Weston, FL 33326, NDC 60505-0589-1. Apotex Corp. Class II Ongoing 20260325
D-0676-2025 Brimonidine Tartrate/Timolol Maleate Ophthalmic Solution, 0.2%/0.5%, a) 5 mL and b) 10 mL, Rx Only, Sterile, Manufactured by: Apotex Inc., Richmond Hill, Ontario, Canada, L4C 5H2, Manufactured for: Apotex Corp., Weston, FL 33326, NDC 60505-0589-1 (5 mL), NDC 60505-0589-2 (10 mL). Apotex Corp. Class II Ongoing 20251008

Frequently asked questions

What is Bromfenac Ophthalmic Solution, 0.07% used for?
1 INDICATIONS AND USAGE Bromfenac Ophthalmic Solution, 0.07% is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. Bromfenac Ophthalmic Solution, 0.07% is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have …

Who makes Bromfenac Ophthalmic Solution, 0.07%?
Apotex Corp. is the labeler of record for Bromfenac Ophthalmic Solution, 0.07%. 4 FDA label records share the active ingredient BROMFENAC SODIUM, so generic and branded versions may come from different companies; the manufacturer named on your pack is the one that matters for any enquiry.

What form does Bromfenac Ophthalmic Solution, 0.07% come in?
administered by ophthalmic. Strengths and pack sizes vary by label, so compare the NDC on your pack with the identifier listed on this page.

Is Bromfenac Ophthalmic Solution, 0.07% prescription or over-the-counter?
The FDA label for this product is recorded as human prescription drug. Marketing status can differ between strengths and countries, so check the dispensing rules where you live.

Are there other products containing BROMFENAC SODIUM?
Yes. 4 FDA drug label records list BROMFENAC SODIUM as the active ingredient. Products with the same active ingredient can usually be substituted only when a prescriber or pharmacist confirms it is appropriate.

Has Bromfenac Ophthalmic Solution, 0.07% been recalled?
5 FDA recall record(s) match this product name or manufacturer. Review the recall and safety notices section on this page and confirm lot numbers against the official FDA enforcement report.

Where does this information come from?
All content is reproduced from FDA Structured Product Labelling data via openFDA. It is provided for identification and reference only and is not medical advice.

This page reproduces FDA Structured Product Labelling data for identification and reference. It is not medical advice, does not diagnose or treat any condition, and does not sell or price any medicine.